# reload+after+2024-01-21 04:43:53.164897
address1§117 Kendrick Street
address2§Suite 450
city§Needham
state§MA
zip§02494
country§United States
phone§617 916 5445
website§https://www.candeltx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.
fullTimeEmployees§76
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Paul-Peter  Tak FMEDSCI, M.D., Ph.D.', 'age': 63, 'title': 'President, CEO & Director', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 1158929, 'exercisedValue': 0, 'unexercisedValue': 302067}, {'maxAge': 1, 'name': 'Dr. Estuardo  Aguilar-Cordova Inf., M.D., Ph.D.', 'age': 64, 'title': 'Founder & Director', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 35083, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Seshu  Tyagarajan Ph.D.', 'age': 56, 'title': 'Chief Technical & Development Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 335269, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Francesca  Barone M.D., Ph.D.', 'age': 45, 'title': 'Chief Scientific Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 518914, 'exercisedValue': 0, 'unexercisedValue': 5858}, {'maxAge': 1, 'name': 'Mr. Jason A. Amello', 'age': 55, 'title': 'CFO, Treasurer & Secretary', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Ileen B. Winick', 'title': 'Chief People Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Susan  Stewart J.D., L.L.M.', 'age': 62, 'title': 'Chief Regulatory Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. William Garrett Nichols M.D., M.S.', 'age': 54, 'title': 'Chief Medical Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.751
priceToSalesTrailing12Months§1315.3844
currency§USD
dateShortInterest§1702598400
forwardEps§-0.91
exchange§NGM
quoteType§EQUITY
shortName§Candel Therapeutics, Inc.
longName§Candel Therapeutics, Inc.
firstTradeDateEpochUtc§1627392600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f9d74846-1850-3a5e-9621-529c7426beb2
gmtOffSetMilliseconds§-18000000
targetHighPrice§11.0
targetLowPrice§8.0
targetMeanPrice§9.5
targetMedianPrice§9.5
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§4.162
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
